Gilead to launch generic versions of its hep C drugs

Gilead is set to produce cheaper authorised generic (AG) versions of its branded hepatitis C treatments from 2019.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

PTAB to review Minnesota patent after Gilead petition

2 June 2020 Gilead Sciences has persuaded the US Patent Trial and Appeal Board to review an antiviral patent owned by the University of Minnesota.

Big Pharma

MSF critical of EPO decision to uphold Gilead’s hepatitis C patent

17 September 2018 The European Patent Office has upheld a patent covering Gilead’s hepatitis C medicine sofosbuvir, despite opposition from humanitarian organisation Médecins Sans Frontières.

Americas

Federal Circuit affirms Merck ‘unclean hands’ verdict

26 April 2018 The US Court of Appeals for the Federal Circuit has affirmed a finding that pharmaceutical company Merck had engaged in misconduct and was not allowed to bring an action against Gilead.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Gilead to launch generic versions of its hep C drugs

More on this story

Editor's picks

Editor's picks

More features